rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

References

• Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217–226. doi:10.1007/s11899-017-0382-128478586
   PubMed Web of Science ®Google Scholar
• Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2012;18(8):1191–1203. doi:10.1016/j.bbmt.2012.01.00822261379
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res. 1998;4(2):311–316. PMID: 9516916.9516916
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22(6):1095–1102. doi:10.1200/JCO.2004.07.13115020611
   PubMed Web of Science ®Google Scholar
• To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530–4540. doi:10.1182/blood-2011-06-31822021832280
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi:10.1200/JCO.2010.28.161820660832
   PubMed Web of Science ®Google Scholar
• van Gorkom G, Finel H, Giebel S, et al. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2017;32(5):295–301. doi:10.1002/jca.2150627614935
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Thrombopoietin: understanding and manipulating platelet production. Annu Rev Med. 1997;48:1–11. doi:10.1146/annurev.med.48.1.19046940
   PubMed Web of Science ®Google Scholar
• Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant. 2003;9(6):405–413. PMID: 12813449.12813449
   PubMed Web of Science ®Google Scholar
• Wang G, Chen W, Wu Y, Li Y, Leng Y, Liu A. Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: a cohort study. Medicine (Baltimore). 2017;96(50):e9302. doi:10.1097/MD.000000000000930229390394
   PubMed Web of Science ®Google Scholar
• Somlo G, Sniecinski I, Ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93(9):2798–2806. PMID: 10216073.10216073
   PubMed Web of Science ®Google Scholar
• Haverkos B, Geyer S, McBride A, et al. Mobilization for autologous stem cell transplantation in Hodgkin’s lymphoma (HL) and non-Hodgkin lymphoma: a single institution experience. Biol Blood Marrow Transplant. 2014;20(2):S111–S112. doi:10.1016/j.bbmt.2013.12.160
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007;40(2):111–118. doi:10.1038/sj.bmt.170570817530003
   PubMed Web of Science ®Google Scholar
• Canales M, Fernández-Jiménez MC, Martín A, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin’s disease. Haematologica. 2001;86(5):494–498. PMID: 11410412.11410412
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49(9):1890–1900. doi:10.1111/j.1537-2995.2009.02202.x19453991
   PubMed Web of Science ®Google Scholar
• Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci. 2017;56(2):190–198. doi:10.1016/j.transci.2016.11.00528034547
   PubMed Web of Science ®Google Scholar
• Herbert KE, Levesque JP, Mills AK, et al. How we mobilize haemopoietic stem cells. Intern Med J. 2011;41(8):588–594. doi:10.1111/j.1445-5994.2011.02544.x21831119
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43(3):181–195. doi:10.1038/bmt.2008.41019139734
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V, Valtola J. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Expert Rev Hematol. 2016;9(8):723–732. doi:10.1080/17474086.2016.120808227355397
   PubMed Web of Science ®Google Scholar
• Salvino MA, Ruiz J. Hematopoietic progenitor cell mobilization for autologous transplantation-a literature review. Rev Bras Hematol Hemoter. 2016;38(1):28–36. doi:10.1016/j.bjhh.2015.07.01126969772
   PubMedGoogle Scholar
• Bilgin YM, de Greef GE. Plerixafor for stem cell mobilization: the current status. Curr Opin Hematol. 2016;23(1):67–71. doi:10.1097/MOH.000000000000020026554889
   PubMed Web of Science ®Google Scholar
• Wagemaker G, Hartong SC, Neelis KJ, Egeland T, Wognum AW. In vivo expansion of hemopoietic stem cells. Stem Cells. 1998;16:185–191. doi:10.1002/stem.5530160822
   PubMedGoogle Scholar
• Wagemaker G, Neelis KJ, Hartong SC, et al. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Stem Cells. 1998;16(6):375–386. doi:10.1002/stem.1603759831863
   PubMed Web of Science ®Google Scholar